Skip to main content
Springer logoLink to Springer
. 2013 Jul 7;49(1):88–102. doi: 10.1007/s12035-013-8489-4

Integrating Pathways of Parkinson's Disease in a Molecular Interaction Map

Kazuhiro A Fujita 1, Marek Ostaszewski 2,3, Yukiko Matsuoka 1, Samik Ghosh 1, Enrico Glaab 2, Christophe Trefois 2, Isaac Crespo 2, Thanneer M Perumal 2, Wiktor Jurkowski 2, Paul M A Antony 2, Nico Diederich 2,4, Manuel Buttini 2, Akihiko Kodama 5, Venkata P Satagopam 2,6, Serge Eifes 2, Antonio del Sol 2, Reinhard Schneider 2,6, Hiroaki Kitano 1,7,8,9, Rudi Balling 2,
PMCID: PMC4153395  PMID: 23832570

Abstract

Parkinson's disease (PD) is a major neurodegenerative chronic disease, most likely caused by a complex interplay of genetic and environmental factors. Information on various aspects of PD pathogenesis is rapidly increasing and needs to be efficiently organized, so that the resulting data is available for exploration and analysis. Here we introduce a computationally tractable, comprehensive molecular interaction map of PD. This map integrates pathways implicated in PD pathogenesis such as synaptic and mitochondrial dysfunction, impaired protein degradation, alpha-synuclein pathobiology and neuroinflammation. We also present bioinformatics tools for the analysis, enrichment and annotation of the map, allowing the research community to open new avenues in PD research. The PD map is accessible at http://minerva.uni.lu/pd_map.

Electronic supplementary material

The online version of this article (doi:10.1007/s12035-013-8489-4) contains supplementary material, which is available to authorized users.

Keywords: Parkinson’s disease, Molecular neuropathology, Knowledge repository, Bioinformatics

Introduction

Parkinson’s disease (PD) is a major neurodegenerative disease, characterized clinically by a range of symptoms, in particular, impaired motor behaviour. The pathogenesis of PD is multi-factorial and age-related, implicating various genetic and environmental factors [1]. Gaps in the understanding of the underlying molecular mechanisms hamper the design of effective disease modifying therapies. Investigation of such a complex disease requires a proper knowledge repository that organizes the rapidly growing PD-related knowledge — a disease map.

The concept of a disease map is relatively new and has found only a limited application in the field of neurodegenerative diseases thus far [2, 3]. Such a map represents diagrammatically interactions between molecular components and pathways reported to play a role in disease pathogenesis and progression. It provides navigation and exploration tools that help the user to locate specific areas of interest and visualize known interactions. Associated analytical tools allow investigators to develop a profound understanding of the disease, detect unexpected interactions and ultimately identify new research hypotheses.

In this paper, we present a PD molecular interaction map that captures and visualizes all major molecular pathways involved in PD pathogenesis. Furthermore, it constitutes a resource for computational analyses and a platform for community level collaborations [4, 5] (see Fig. 1). We also present how a set of bioinformatics tools applied to the map can facilitate in-depth knowledge extraction and continuous curation.

Fig. 1.

Fig. 1

The concept of Parkinson's disease map and its possibilities. The PD map is a knowledge repository bringing together different molecular mechanisms and pathways considered to be the key players in the disease. The current focus of the map is illustrated by the pieces in the “PD puzzle” These modules include synaptic and mitochondrial dysfunction, failure of protein degradation systems, α-synuclein pathobiology and misfolding, and neuroinflammation. Processes important in PD-associated neurodegeneration, such calcium homeostasis or apoptosis, are discussed within their appropriate context in the main text, and included into the PD map pathways. The PD map is represented as a graph constructed with all gene-regulatory protein and metabolic interactions extracted from published data. Currently the map has 2,285 elements and 989 reactions supported by 429 articles and 254 entries from publicly available bioinformatic databases. It is compliant with standardized graphical representation, Systems Biology Graphical Notation (SBGN) [265]. This standardized representation of the map could become a common language for the PD research community to discuss disease-related molecular mechanisms [5]. Detailed contents of the PD map are accessible at http://minerva.uni.lu/MapViewer/map?id=pdmap (Online resource 1) as an SBML file (Online resource 2) and in Payao [264]. The map can be updated with information from the PD research community, as well as by searching bioinformatics databases. Exploration and analysis of the content has the potential to broaden knowledge on the molecular processes in PD, generate of new hypotheses on disease pathogenesis, or prioritize the most interesting areas and molecules for investigation. Approaches to facilitate this knowledge acquisition process are discussed in detail in the section “Annotation, enrichment and Analysis of the PD Map

The paper is divided into two parts. In the first part, we review the pathways implicated in PD, with a focus on synaptic and mitochondrial dysfunction, α-synuclein pathobiology, failure of protein degradation systems, neuroinflammation and apoptosis. In the second part of the paper, we demonstrate how the PD map interfaces with bioinformatics tools and databases for its content annotation, enrichment with experimental results, and analysis of its complex structure and dynamics. The PD map is accessible under http://minerva.uni.lu/pd_map (Online resource 1), as a SBML file (Online resource 2), and Payao, a community platform for pathway model curation [264].

Neurodegeneration in Parkinson’s Disease Arises from Dysregulation of Interlinked Molecular Pathways

The major pathological feature of PD is the progressive degeneration of the nigrostriatal system, leading to the loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc) [6]. The degeneration of the nigrostriatal pathway and subsequent loss of striatal dopamine contributes to the cardinal clinical motor symptoms: tremor, rigidity, bradykinesia and postural instability [7]. Although treatments such as dopamine substitution and deep brain stimulation alleviate many of the motor symptoms, there is no disease-modifying therapy preventing the progressive loss of DA neurons [8].

Susceptibility for PD is modulated by various environmental factors [913], genetic predisposition or risk factors [14] and epigenetic alterations [15, 16].1 Exposure to pesticides and industrial agents has been associated with an increased risk for PD [17, 18], but to date none of these agents have been consistently identified as a causal factor for PD [19]. It is known that exposure to inhibitors of mitochondrial respiration [2025] are sufficient to induce PD symptoms in humans and DA neurodegeneration in animal models.

In this paper, we focus on DA neurons as a major point of convergence in PD disease pathways. However, pathogenic pathways leading to the demise of DA neurons may impact any neuronal population affected in PD, including those of the autonomic ganglia [26, 27]. The demise of these populations may contribute to a range of PD-typical non-motor symptoms hampering the life of PD patients, such as constipation and dysautonomia (ganglia of autonomous nervous system), cognitive decline and REM sleep behaviour (cholinergic neurons of the nucleus basalis of Meynert, noradrenergic coeruleus–subcoeruleus complex), depression and apathy (serotinergic caudal raphe nuclei, cholinergic gigantocellular reticular nucleus) [28, 29].

Vulnerability and Preferential Loss of Midbrain Dopaminergic Neurons

SNpc DA neurons are the most vulnerable population of neurons in PD. It has been suggested that their loss is multifactorial and related to the characteristic features of these cells: complex morphology, high energy demand, high calcium flux, and dopamine metabolism [30]. Consequently, these neurons are particularly susceptible to various stressors, which contribute to their preferential loss (see Fig. 2).

Fig. 2.

Fig. 2

Pathways implicated in PD and their relationship to susceptibility factors of SNpc DA neurons. The black arrows represent direct molecular interactions between the dysregulated pathways. Red arrows denote pathways affected by or generating ROS. Dashed lines represent indirect associations of these pathways and neurodegeneration. Susceptibility factors of SNpc DA neurons associated with a given pathway are indicated by their corresponding symbols

SNpc DA neurons have one of the longest yet most dense arborisation of all neurons [31, 32]. They project to the striatum, providing it with DA [33, 34]. These neurons have long, thin, mostly unmyelineated axons [35] and up to 150,000 presynaptic terminals per neuron [30]. The high energy demand required to support synaptic activity, compensation for the potential risk of depolarization in the unmyelinated membrane, and axonal transport over long distances put a huge burden on the mitochondria. Interestingly, toxins that perturb the energy production and the axonal transport of mitochondria [36], cause parkinsonism in humans and preferential loss of DA neurons in animal models [22, 36, 37]. Finally, the large number of synapses increases the risk for local α-synuclein (α-syn) misfolding (see sections “Synaptic Dysfunction” and “α-Synuclein Misfolding and Pathobiology”).

SNpc DA neurons can fire autonomously and have specific calcium L-type Cav 1.3 channels that regulate this pacemaking activity [38, 39]. The resulting high intracytosolic Ca2+ concentrations induce cellular stress, elevate the levels of reactive oxygen species (ROS), and increase demand for calcium buffering, which is handled by the endoplasmic reticulum (ER) and the mitochondria. Maintaining proper calcium homeostasis in such an environment increases again the energy needs. In contrast, neighbouring dopamine neurons in the ventral tegmental area use Na+ channels for pacemaking and are relatively spared in PD [37].

Cytosolic DA also contributes to the vulnerability of DA neurons, primarily because its metabolism induces oxidative and nitrative stress in an age-dependent manner [4042]. Neurotoxicity of DA increases with its concentration, which is thought to be regulated by Ca2+ concentration [43]. Additionally, dopamine metabolism is involved in a number of PD-associated pathways, as it can impair synapse function, inhibit protein degradation and disturb mitochondrial dynamics by inhibiting the function of Parkin.

Ageing, the primary risk factor for PD, especially affects DA neurons (see Fig. 2). α-Syn accumulation increases with age in the SNpc and correlates with the loss of DA neurons in non-human primates [42]. This could be linked to the age-related impairment of the two protein degradation systems: the ubiquitin–proteasome system (UPS) [42] and the autophagy–lysosome system [44]. ROS accumulate in an ageing brain [42, 45], partially due to mitochondria dysfunction, as mitophagy2 is decreased with ageing [45, 46]. Finally, the threshold required to trigger a neuroinflammatory response may decrease with age, since glial activation in SNpc increases in the ageing brain [42, 47].

Synaptic Dysfunction

The main function of a synapse is to establish a connection between neurons allowing communication via chemical or electric signals. The synapse has emerged as a neuronal structure highly susceptible to a variety of chronic insults [4851]. Below, we discuss the increasing evidence indicating that synapses are also affected in PD, and that their dysfunction and demise contributes to the disease.

α-Syn is a presynaptic protein. Point mutations, duplications or triplications of its gene are associated with familial PD [5254]. In cultured neurons, it transiently associates with synaptic vesicles prior to neurotransmitter release, upon which it rapidly redistributes to the cytosol [55]. Association of α-syn with the synaptic vesicle may occur through its binding to SNARE complex proteins [56], and, as shown in mice, α-syn positively influences functional SNARE levels [57]. Similarly, upregulation of α-syn in synapses and cell somas of cultured neurons protects against oxidative stress [58]. However, the protective effect of α-syn is limited to a narrow concentration range, since high levels of α-syn cause familial PD [53]. Even modest overexpression of α-syn has been reported to markedly inhibit neurotransmitter release [59]. Also, α-syn forms potentially pathogenic micro-aggregates in the synapse [60]. Another protein involved familial and sporadic PD, LRRK2, is also present in the synapse. Its experimentally induced upregulation or knockdown impairs the dynamics of synaptic vesicle release and recycling [61, 62]. However, the influence of mutated or dysfunctional LRRK2 on these processes in PD remains to be investigated.

A number of other PD-related pathological events might affect synapses. Synapses of the nigrostriatal pathway, with their high level of α-syn and dopamine, are likely to be the major site of the formation of toxic adducts of α-syn and oxidized DA [40, 63, 64]. Furthermore, the energy demands of synapses may be compromised by dysfunctional mitochondrial respiration, turnover, or axonal transport [65]. Locally dysfunctional protein degradation and turnover may directly affect synaptic function and plasticity [66].

Mitochondrial Dysfunction

Mitochondria are highly dynamic organelles essential for a range of cellular processes including ATP production, ROS management, calcium homeostasis, and control of apoptosis. The maintenance of mitochondrial homoeostasis by mitophagy involves multiple factors ranging from the control of mitochondrial fusion and fission to mitochondrial motility [67]. These processes are strongly related to proteins involved in familial and sporadic PD [65, 68, 69].

A number of proteins associated with familial PD are related to mitochondrial function [70], with PINK1 and Parkin playing a particularly important role. Control of mitochondrial turnover and protection against oxidative stress are mediated via the kinase activity of PINK1 targeting Parkin [71], HTRA2 [72] and TRAP1[73] proteins. In turn, mitophagy is driven by PINK1-mediated translocation of Parkin from the cytosol to mitochondria [71, 74]. Importantly, both mitophagy [75, 76] and transcriptional control of mitochondrial biogenesis [7779] depend on the E3 ubiquitin ligase activity of Parkin.

Familial PD genes are also implicated in ROS production by mitochondria. Mitochondrial respiration and calcium balance are perturbed by PINK1 deficiency [80, 81]. The resulting reduced mitochondrial calcium capacity and increased ROS could lower the threshold for mitochondrial outer membrane permeabilization (MOMP) and thereby increase the vulnerability for cell death [80]. Additional detrimental downstream effects of excessive ROS are mitochondrial DNA damage and inflammation [65, 82]. It has been suggested that DJ1 works in parallel to the PINK1–Parkin pathway to maintain mitochondrial function in the presence of an oxidative environment [83]. DJ1 was shown to interact with a mitochondrial protein mortalin, which maintains mitochondrial homeostasis and antagonizes oxidative stress injury [84]. Remarkably, Parkin overexpression has been demonstrated to prevent mitochondrial dysfunction caused by a mortalin knockdown [85].

Mitochondrial trafficking is necessary for proper energy supply. This process is particularly demanding in long axons of DA neurons. Recent findings suggest that mitochondrial transport may be affected in PD. Axonal transport of mitochondria along the microtubules is directly influenced by PINK1 through its supporting role in the kinesin motor complex [86]. Also, PINK1 and Parkin may play an important role in the process of quarantining the damaged mitochondria prior to their clearance [87]. However, the role of PINK1 in the dynamics of mitochondrial trafficking is not yet fully understood [88]. Mitochondrial trafficking may also be impaired by Parkin, α-syn, or LRRK2 as they modulate microtubule stability [8992], or by formation of α-syn aggregates [93].

Finally, other proteins associated with familial PD have recently been linked to mitochondrial pathways. UCHL1-mediated cell death can be attenuated by mitochondrial protein HTRA2 [94], ATP13A2 regulates mitochondrial bioenergetics through macroautophagy [95], VPS35 mediates vesicle transport between mitochondria and peroxisomes [96], and EIF4G1 is involved in stress related protection of mitochondria [97].

Failure of Protein Degradation Systems

In long-lived post-mitotic cells, such as neurons, the degradation systems assuring the removal of damaged, dysfunctional cellular structures play a key role in cellular homeostasis. These degradation systems are involved in the clearance of defective cellular structures such as misfolded or damaged proteins, and dysfunctional organelles such as defective mitochondria [98]. The two major degradation systems are the UPS and the autophagy–lysosome system. The complex machinery and biology of these two systems have been extensively reviewed elsewhere [66, 99101]. The dysfunction of clearance systems, especially in the synapse, can lead to the accumulation of α-syn and defective mitochondria. These, in turn, can interfere with proper synaptic function, lead to the formation of toxic assemblies or aggregates, or impair energy metabolism and cause oxidative stress.

Genetic and pathological evidence strongly indicate the involvement of defective clearance systems in PD [102104]. Interestingly, patients with Gaucher’s disease, a lysosomal storage disorder [105, 106], have an increased risk for PD and accumulate α-syn in their brains [107]. Mutated forms of α-syn have been reported to inhibit their own degradation by chaperone-mediated autophagy (CMA), while DA-modified α-syn also blocks CMA degradation of other proteins [103]. Finally, pathological observations in PD autopsy brains and brains of PD animal models show an increased number of autophagy vacuoles and other autophagy markers [108, 109]. Interestingly, neurons containing Lewy bodies (LB) were shown to have decreased UPS and lysosomal markers [110].

While this evidence demonstrates the involvement of cellular clearance mechanisms in PD, it is unclear whether that involvement is primarily beneficial or detrimental. It has been argued that exaggerated clearance activity may contribute to neuronal injury [111, 112]. The predominant view, however, is that the removal of abnormal proteins and organelles is neuroprotective [102, 113118].

α-Synuclein Misfolding and Pathobiology

The pathobiology of α-syn is implicated in a number of pathways involved in PD. α-Syn is an intrinsically disordered protein [119], which can spontaneously and dynamically adopt either physiological or misfolded conformations. The latter contains β-sheet structure, which promotes oligomerisation and fibrilisation [120122]. High-order oligomeric and pre-fibrillar forms are thought to be cytotoxic, while fibrillar and aggregated forms may be harmless, detoxified depositions [119, 123]. This is still controversial, since familial PD α-syn mutants promote both misfolding and aggregation of α-syn, suggesting a pathological role of this process [103, 121, 124, 125].

Mutated, misfolded or overexpressed α-syn is involved in a number of pathways associated with degeneration of SNpc DA neurons. It is thought to impair synapse function [126129] and to affect the respiration, morphology and turnover of mitochondria [130134]. Axonal transport might be impaired by misfolded α-syn through perturbation of microtubule assembly [135137], especially together with MAPT protein [138143]. Also, oligomers of mutant α-syn induce chronic ER stress [125, 144], which seems to precede actual neurodegeneration [145]. Finally, α-syn degradation by CMA [146] might be perturbed by mutated or dopamine-modified α-syn [103, 146, 147]. Reduction of lysosomal activity by α-syn overexpression might lead to α-syn accumulation [148], suggesting a vicious loop of CMA deficiency and α-syn misfolding. The proteasome system has also been reported to be inhibited either by α-syn mutants [149151], or oligomers [152].

Recent studies suggest that α-syn aggregates spread between cells and that this contributes to the PD disease process [123, 153]. This hypothesis is supported by reports of protein inclusions detected in previously unaffected DA neurons grafted into the striatum of PD patients [154156]. The existence of a neuron-to-neuron transfer mechanism for misfolded α-syn has been shown in cell culture, primary mouse neurons and mouse models [157159]. Moreover, it was observed that different types of cellular stress associated with PD pathogenesis, such as misfolded protein accumulation [160], proteasomal and mitochondrial dysfunction [161], are able to increase secretion of α-syn and its aggregates.

It has been shown that exogenous α-syn preformed fibrils might promote the aggregation of endogenous α-syn in neuronal cells [158, 159, 162] impairing neural function [158, 159]. Taken together, these results suggest that misfolded α-syn can be secreted and taken up, introducing additional cellular stress and promoting further protein misfolding.

Neuroinflammation

Neuroinflammation and chronic activation of the immune system are pathological processes associated with all chronic neurodegenerative diseases, such as PD, AD or multiple sclerosis [163]. Although the involvement of the adaptive immune system in PD-related neuroinflammation has been suggested [164, 165], in particular in the context of α-syn and neuromelanin [166, 167], current research of neuroinflammation in PD focuses primarily on the innate immune system. Of particular interest are microglia3 [168] and astrocytes4 [169, 170].

Microglia constantly explore and monitor the local environment [171, 172], modulating the response of the immune system in relation to the level of their perturbation. At the first sign of stress, they produce and release anti-inflammatory cytokines and supportive growth factors [168]. Neurons play an active role in regulating the microglial response. Many of their products inhibit microglia activation by binding to specific microglial receptors [173177].

The SNpc is a brain region that may be especially vulnerable to elevated neuroinflammation. The SNpc contains more microglia [178] and less astrocytes than other brain regions [179]. With a high microglial density promoting the inflammatory response, and low astroglial density to downregulate it, neuroinflammation in the SNpc may be particularly strong. Moreover, SNpc neurons contain neuromelanin, which has been shown to activate microglia [180] and could be another factor promoting neuroinflammation.

The response of glial cells in the context of PD has been studied in humans, animal models and cell cultures. The presence of reactive microglia in human post-mortem brain tissue has been reported in PD patients [181] and in people exposed to MPTP [182]. In animal models of PD, microglial activation has been studied in primates [183], mice [184] and rats [185], supporting the notion that neuroinflammation is intrinsically associated with the PD pathological process. In cellular co-cultures of neuronal cells and microglia, neuronal injury drives microglia activation, which in turn enhances neurodegeneration [186].

In vitro systems demonstrate that the delicate balance between protective and detrimental effects of glial response might be disrupted by PD-related stress factors. Microglia can detect misfolded α-syn [187, 188] and increase neurotoxicity by producing ROS and pro-inflammatory cytokines [189, 190]. In turn, activated microglia expressing LRRK2 with a PD-related mutation produce more pro-inflammatory cytokines than corresponding cells expressing WT LRRK2 [191]. Deficiency in Parkin may indirectly promote microglia activation by increasing neuronal vulnerability for inflammation-related stress [192] and disturbing the neuron–microglia balance. Finally, DJ-1 deficiency in astrocytes might contribute to neurodegeneration by deregulating their neuroinflammatory response [193].

In summary, many in vitro PD models indicate a detrimental role of microglia. However, the situation in vivo is less clear, even though protective effects of anti-inflammatory compounds such as minocycline have been reported in models of PD [194].

Neuronal Death Through Apoptosis-Related Mechanisms

Degeneration of DA neurons is the final consequence of dysregulated cellular processes, leading to neuronal death [195]. Neurodegeneration by apoptosis typically proceeds through one of two signalling cascades, termed the intrinsic and extrinsic pathways [196, 197].

The intrinsic pathway can be induced by intracellular stress, leading to MOMP that is controlled through proteins of the BCL-2 family. As a result, cytochrome c is released from the mitochondrial intermembrane space, leading to formation of an apoptosome and subsequent execution of apoptosis by activation of caspases 3 and 7. Studies in animal models of PD suggest the BCL-2 family is a key target for attenuating neurodegeneration of DA neurons [198202].

Additionally, an important link between PD and the activation of apoptosis comes from studies investigating the roles of familial PD genes. It has been shown that disease-related LRRK2 mutations R1441C, Y1699C and G2019S promote mitochondria-dependent apoptosis [203]. PINK1 and Parkin, in turn, protect against stress-induced cytochrome c release, while their mutations might fail to attenuate basal neuronal pro-apoptotic activity [204206]. Importantly, failure of the protein degradation system could also contribute to apoptosis via the intrinsic pathway. It has been proposed that lysosome membrane permeabilization is induced by ROS and occurs upstream and downstream of MOMP [207, 208]. Finally, DA-mediated activation of the intrinsic pathway may contribute to selective DA neuron degeneration [209].

The extrinsic apoptosis pathway is activated by extracellular signalling, and diverges into two sub-pathways: one directly activating caspase 3 and 7, the other causing MOMP. Neuroinflammation could be a major factor in this process [165, 187, 210], promoting neuronal apoptosis either by oxidative insults [211] or by pro-inflammatory cytokines [212, 213].

In summary, both apoptosis pathways appear to be the convergence point of different pathways dysregulated in PD. Still, therapeutic interventions may be most efficacious in maintaining DA neuron functionality if aimed at the upstream events of apoptosis. Indeed, as the apoptotic process is advanced, the intervention may be too late.

Annotation, Enrichment and Analysis of the PD Map

Dysregulated pathways implicated in PD are strongly coupled, and their interconnections need to be represented in an integrated and comprehensive way to be studied efficiently. Our PD map allows navigation through information on PD-associated mechanisms, and constitutes an interface to well-established tools and methods for updating, enriching, and analysing its contents (see Fig. 3).

Fig. 3.

Fig. 3

The workflow and an illustration of PD map functionalities. a The PD map can be automatically enriched with experimental data and annotated with information from text and bioinformatics databases. The analysis requires no external data sources. b A simplified representation of the PD map is given, with circles (nodes) as map elements and lines (edges) as interactions (uni- or bi-directional). Enrichment: green and red nodes represent up- and downregulated genes, respectively, derived from experimental data; a predicted new map component (square) shares interaction with existing map components (dashed lines) and matches their expression profile. Analysis: nodes with high centrality (blue) play a key role in the network topology and indicate molecules regulating many processes; detection of paths (thick lines) highlights non-trivial relations between elements of a biological process; kinetic modelling reveals temporal dependencies between behaviour of different molecules. Annotation: text mining of PD-related articles suggests new interactions in the map (thick dashed line) and facilitates handling of a huge number of publications; each map element is annotated with information from various bioinformatics databases giving easy access to information about interesting elements

Annotation of the PD Map Using Bioinformatic Databases

We have enriched the elements of the PD map using a number of publicly available databases [214230]. Information on official gene symbol, synonyms, description and chromosomal location; association with biological processes and diseases; or molecular interacting partners have been embedded within the map. Annotation of the contents of the PD map facilitates the knowledge exploration by providing additional information about map elements and their interactions, and is easily accessible online (see Fig. 3b for illustration and Online resource 1 for details).

Exploration of the Map Using Integrative Expression Analysis

Recently, a variety of PD-related large-scale datasets have become publicly available, including microarray gene expression data for human post mortem samples from different regions of the brain [231234], human whole-blood samples [235], and samples from animal [236] and cell culture models [237]. This experimental data can be visualized on the PD map or used to predict new map elements and interactions [238240].

Visualization of gene deregulation in PD-related microarray datasets [231234] is possible via a variety of methods for candidate disease gene or protein prioritizations [241244]. We have chosen an approach combining significance scores [245] for differentially expressed genes in multiple studies, and prepared a colour-coded version of the map highlighting upregulation in green and downregulation in red (see the online PD map and Online resource 1). This gives an immediate overview of pathways that are affected by dysregulated genes.

One of the major advantages of the PD map is the possibility to predict new elements and interactions on the basis of the map contents and experimental data. To achieve this, publicly available human molecular interaction data [242] are obtained for the PD map elements, extending the number of interactions. Then, an automated, graph-theoretic approach [243] prioritizes candidate disease proteins that are densely interconnected in the extended PD map, and whose gene expression levels are differentially expressed in the microarray PD samples. We have combined the abovementioned experimental microarray [231234] and protein-protein interaction data [242] to demonstrate the usage of this approach. The extended PD map containing the prioritized new proteins can be found in Online resource 1.

PD Map as a Network: from Structural Analysis to Kinetic Models

The PD map is a large, complex network integrating metabolic reactions, gene regulation, and signalling processes. Exploring how different elements in the network may influence each other is difficult and non-intuitive. Graph-theoretical methods aim to bridge the gap between our understanding of the role of single elements in a cellular network and the properties of this network as whole [246, 247]. These methods aim to identify key network nodes (genes, proteins), edges (molecular interactions) or modules5 (subnetworks) [246].

Basic properties of individual network elements such as node centrality6 indicate their global role in the whole network. In turn, analysis of inter-modular communicationf in the network indicates a how given molecule, complex or interaction can affect communication between modules [248, 249]. More advanced, functional dependencies between elements in the network can be revealed by methods exploring the relationships of all possible paths between network elements and selected molecular dysfunctions [250] (see Fig. 3b for illustration). Examples of network analysis applied to the PD map can be found in Online resource 1.

Most of the connections on the PD map depict real physical interactions between biomolecules. Currently, the PD map contains no information on kinetics of these interactions; however, they can be easily assigned and analysed mathematically [251]. The PD map is compliant with the Systems Biology Markup Language (SBML) standard [252], used by commonly available software to build kinetic models and run simulations [253]. Although assigning kinetic parameters to all interactions in the PD map is a truly challenging task, describing kinetics of a certain process representing a module within the PD map is feasible. In-depth analysis of the dynamics of a process can provide insight as to how elements of the process change quantitatively and over time (see Fig. 3b for illustration) and assess their influence on the related components in the map. This can lead to new hypotheses that are impossible to discover by visual examination or analysis of static network topology [254]. There are many successful examples, where similar bottom–up modelling has been applied to neurobiology related systems [255258].

In summary, structural network analysis allows for detection of elements key to PD pathogenesis represented in the map. This can serve as a basis for new hypotheses and prioritization of targets for further investigation.

Conclusions and Perspectives

PD is a neurodegenerative disease involving a complex interplay of environmental and genetic factors. It becomes increasingly important to develop new approaches to organize and explore the exploding knowledge of this field. The PD map is a computer-based knowledge repository, representing diagrammatically molecular mechanisms of PD in a structured and standardized way. It can be linked to bioinformatics tools facilitating exploration and updating the contents of the map using bioinformatic annotations.

The main insights into molecular pathology of PD come from studies on familial PD and GWAS. In the future, massive use of next-generation sequencing will provide even more data that might contribute to PD. The PD map facilitates integration and visualization of large experimental datasets, allowing analyzing them in the context of disease mechanisms.

Discovering causal factors of PD pathogenesis is difficult because molecular pathways dysregulated in neurodegeneration are interconnected and influence each other. Analysis of the topology and dynamics of molecular interactions within and across different pathways represented in the PD map may help to uncover key factors in PD pathology. For instance, the role of neuroinflammation in the pathological cascade in PD remains unclear, while the apoptosis, clearly a downstream factor of PD, involves other mechanisms implicated in PD, like protein degradation or mitochondrial quality control. Consequential steps of PD pathology can be elucidated by the global, systems level analysis of all implicated factors.

The map has reached substantial size and complexity. Keeping it up-to-date and refining it with limited resources will be a challenge. We foresee the PD map as a crowd-sourcing project, where an interested and knowledgeable research community is engaged in solving a problem [259262], similar to WikiPathways or Payao [263, 264], but focused on disease-related mechanisms. Thus, the PD community will easily explore and curate the PD-related knowledge in an online manner, ensuring that individual contributions are recognized.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1 (213.9KB, pdf)

(PDF 211 kb)

ESM 2 (11.4MB, xml)

(XML 11.3 mb)

ESM 3 (404.8KB, pdf)

(PDF 404 kb)

ESM 4 (137.2KB, pdf)

(PDF 137 kb)

ESM 5 (290.4KB, pdf)

(PDF 290 kb)

Acknowledgments

We are grateful to Angela Hogan for language correction assistance.

Conflict of interest

The authors declare that they have no conflict of interest.

Footnotes

1

Epigenetic alterations — secondary, environmentally induced changes of gene expression.

2

Mitophagy — autophagy of mitochondria.

3

Microglia — the most abundant of the resident macrophage populations in the CNS.

4

Astrocytes — glial cells that play a supportive role for neurons and modulate microglia response.

5

Module — in the PD map by a module (subgraph, subnetwork) we understand elements and interactions participating in the same pathway or serve similar biological function. Inter-modular communication denotes all interactions linking different modules.

6

Node centrality — a measure describing how important a given node is for the connectivity of the entire network.

K. Fujita and M. Ostaszewski contributed equally to this work.

References

  • 1.Obeso JA, Rodriguez-Oroz MC, Goetz CG, et al. Missing pieces in the Parkinson’s disease puzzle. Nat Med. 2010;16:653–661. doi: 10.1038/nm.2165. [DOI] [PubMed] [Google Scholar]
  • 2.Caron E, Ghosh S, Matsuoka Y, et al. A comprehensive map of the mTOR signaling network. Mol Syst Biol. 2010;6:453. doi: 10.1038/msb.2010.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Mizuno S, Iijima R, Ogishima S, et al. AlzPathway: a comprehensive map of signaling pathways of Alzheimer’s disease. BMC Syst Biol. 2012;6:52. doi: 10.1186/1752-0509-6-52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Ghosh S, Matsuoka Y, Asai Y, et al. Software for systems biology: from tools to integrated platforms. Nat Rev Genet. 2011;12:821–832. doi: 10.1038/nrg3096. [DOI] [PubMed] [Google Scholar]
  • 5.Kitano H, Ghosh S, Matsuoka Y. Social engineering for virtual “big science” in systems biology. Nat Chem Biol. 2011;7:323–326. doi: 10.1038/nchembio.574. [DOI] [PubMed] [Google Scholar]
  • 6.Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet. 2009;373:2055–2066. doi: 10.1016/S0140-6736(09)60492-X. [DOI] [PubMed] [Google Scholar]
  • 7.Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368–376. doi: 10.1136/jnnp.2007.131045. [DOI] [PubMed] [Google Scholar]
  • 8.Meissner WG, Frasier M, Gasser T, et al. Priorities in Parkinson’s disease research. Nat Rev Drug Disc. 2011;10:377–393. doi: 10.1038/nrd3430. [DOI] [PubMed] [Google Scholar]
  • 9.Dick FD, De Palma G, Ahmadi A, et al. Environmental risk factors for Parkinson’s disease and parkinsonism: the Geoparkinson study. Occup Environ Med. 2007;64:666–672. doi: 10.1136/oem.2006.027003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Goldman SM, Tanner CM, Oakes D, et al. Head injury and Parkinson’s disease risk in twins. Ann Neurol. 2006;60:65–72. doi: 10.1002/ana.20882. [DOI] [PubMed] [Google Scholar]
  • 11.Ritz B, Ascherio A, Checkoway H, et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol. 2007;64:990–997. doi: 10.1001/archneur.64.7.990. [DOI] [PubMed] [Google Scholar]
  • 12.Hu G, Bidel S, Jousilahti P, et al. Coffee and tea consumption and the risk of Parkinson’s disease. Mov Disord. 2007;22:2242–2248. doi: 10.1002/mds.21706. [DOI] [PubMed] [Google Scholar]
  • 13.Saunders-Pullman R. Estrogens and Parkinson disease: neuroprotective, symptomatic, neither, or both? Endocrine. 2003;21:81–87. doi: 10.1385/ENDO:21:1:81. [DOI] [PubMed] [Google Scholar]
  • 14.Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med. 2012;2:a008888. doi: 10.1101/cshperspect.a008888. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Marques SCF, Oliveira CR, Pereira CMF, Outeiro TF. Epigenetics in neurodegeneration: a new layer of complexity. Prog Neuro-psychopharmacol Biol Psychiatry. 2011;35:348–355. doi: 10.1016/j.pnpbp.2010.08.008. [DOI] [PubMed] [Google Scholar]
  • 16.Migliore L, Coppedè F. Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutat Res. 2009;667:82–97. doi: 10.1016/j.mrfmmm.2008.10.011. [DOI] [PubMed] [Google Scholar]
  • 17.Schapira AHV. Aetiopathogenesis of Parkinson’s disease. J Neurol. 2011;258:S307–S310. doi: 10.1007/s00415-011-6016-y. [DOI] [PubMed] [Google Scholar]
  • 18.Priyadarshi A, Khuder SA, Schaub EA, Priyadarshi SS. Environmental risk factors and Parkinson’s disease: a metaanalysis. Environ Res. 2001;86:122–127. doi: 10.1006/enrs.2001.4264. [DOI] [PubMed] [Google Scholar]
  • 19.Dick FD. Parkinson’s disease and pesticide exposures. Br Med Bull. 2006;79–80:219–231. doi: 10.1093/bmb/ldl018. [DOI] [PubMed] [Google Scholar]
  • 20.Davis GC, Williams AC, Markey SP, et al. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1979;1:249–254. doi: 10.1016/0165-1781(79)90006-4. [DOI] [PubMed] [Google Scholar]
  • 21.Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979–980. doi: 10.1126/science.6823561. [DOI] [PubMed] [Google Scholar]
  • 22.Betarbet R, Sherer TB, MacKenzie G, et al. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci. 2000;3:1301–1306. doi: 10.1038/81834. [DOI] [PubMed] [Google Scholar]
  • 23.Thiruchelvam M, Richfield EK, Baggs RB, et al. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson’s disease. J Neurosci. 2000;20:9207–9214. doi: 10.1523/JNEUROSCI.20-24-09207.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Gash DM, Rutland K, Hudson NL, et al. Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity. Ann Neurol. 2008;63:184–192. doi: 10.1002/ana.21288. [DOI] [PubMed] [Google Scholar]
  • 25.Goldman SM. Trichloroethylene and Parkinson’s disease: dissolving the puzzle. Expert Rev Neurother. 2010;10:835–837. doi: 10.1586/ern.10.61. [DOI] [PubMed] [Google Scholar]
  • 26.Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197–211. doi: 10.1016/s0197-4580(02)00065-9. [DOI] [PubMed] [Google Scholar]
  • 27.Poulopoulos M, Levy OA, Alcalay RN. The neuropathology of genetic Parkinson’s disease. Mov Disord. 2012;000:1–12. doi: 10.1002/mds.24962. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Wolters EC. Non-motor extranigral signs and symptoms in Parkinson’s disease. Parkinsonism & Relat Disord. 2009;15(Suppl 3):S6–S12. doi: 10.1016/S1353-8020(09)70770-9. [DOI] [PubMed] [Google Scholar]
  • 29.Ferrer I, López-Gonzalez I, Carmona M, et al. Neurochemistry and the non-motor aspects of PD. Neurobiol Dis. 2012;46:508–526. doi: 10.1016/j.nbd.2011.10.019. [DOI] [PubMed] [Google Scholar]
  • 30.Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson’s disease. Trends Neurosci. 2007;30:244–250. doi: 10.1016/j.tins.2007.03.009. [DOI] [PubMed] [Google Scholar]
  • 31.Matsuda W, Furuta T, Nakamura KC, et al. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J Neurosci. 2009;29:444–453. doi: 10.1523/JNEUROSCI.4029-08.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Matsuda W. Imaging of dopaminergic neurons and the implications for Parkinson’s disease. Syst Biol Parkinson’s Dis. 2012 [Google Scholar]
  • 33.Parent M, Parent A (2006) Relationship between axonal collateralization and neuronal degeneration in basal ganglia. J Neural Transm Suppl 85–8 [DOI] [PubMed]
  • 34.Schmitz Y, Luccarelli J, Kim M, et al. Glutamate controls growth rate and branching of dopaminergic axons. J Neurosci. 2009;29:11973–11981. doi: 10.1523/JNEUROSCI.2927-09.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Braak H, Bohl JR, Müller CM, et al. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson’s disease reconsidered. Mov Disord. 2006;21:2042–2051. doi: 10.1002/mds.21065. [DOI] [PubMed] [Google Scholar]
  • 36.Kim-Han JS, Antenor-Dorsey JA, O’Malley KL. The Parkinsonian mimetic, MPP+, specifically impairs mitochondrial transport in dopamine axons. J Neurosci. 2011;31:7212–7221. doi: 10.1523/JNEUROSCI.0711-11.2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003;39:889–909. doi: 10.1016/s0896-6273(03)00568-3. [DOI] [PubMed] [Google Scholar]
  • 38.Chan CS, Guzman JN, Ilijic E, et al. “Rejuvenation” protects neurons in mouse models of Parkinson’s disease. Nature. 2007;447:1081–1086. doi: 10.1038/nature05865. [DOI] [PubMed] [Google Scholar]
  • 39.Surmeier DJ, Guzman JN, Sanchez-Padilla J, Schumacker PT. The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson’s disease. Neuroscience. 2011;198:221–231. doi: 10.1016/j.neuroscience.2011.08.045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Asanuma M, Miyazaki I, Ogawa N. Dopamine- or l-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease. Neurotox Res. 2003;5:165–176. doi: 10.1007/BF03033137. [DOI] [PubMed] [Google Scholar]
  • 41.Cantuti-Castelvetri I, Shukitt-Hale B, Joseph JA. Dopamine neurotoxicity: age-dependent behavioral and histological effects. Neurobiol aging. 2003;24:697–706. doi: 10.1016/s0197-4580(02)00186-0. [DOI] [PubMed] [Google Scholar]
  • 42.Collier TJ, Kanaan NM, Kordower JH. Ageing as a primary risk factor for Parkinson’s disease: evidence from studies of non-human primates. Nat Rev Neurosci. 2011;12:359–366. doi: 10.1038/nrn3039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Mosharov EV, Larsen KE, Kanter E, et al. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron. 2009;62:218–229. doi: 10.1016/j.neuron.2009.01.033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Rubinsztein DC, Mariño G, Kroemer G. Autophagy and aging. Cell. 2011;146:682–695. doi: 10.1016/j.cell.2011.07.030. [DOI] [PubMed] [Google Scholar]
  • 45.Mammucari C, Rizzuto R. Signaling pathways in mitochondrial dysfunction and aging. Mech Ageing Dev. 2010;131:536–543. doi: 10.1016/j.mad.2010.07.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Green DR, Galluzzi L, Kroemer G. Mitochondria and the autophagy–inflammation–cell death axis in organismal aging. Science. 2011;333:1109–1112. doi: 10.1126/science.1201940. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Venkateshappa C, Harish G, Mythri RB, et al. Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implications for Parkinson’s disease. Neurochem Res. 2012;37:358–369. doi: 10.1007/s11064-011-0619-7. [DOI] [PubMed] [Google Scholar]
  • 48.Mallucci GR. Prion neurodegeneration: starts and stops at the synapse. Prion. 2009;3:195–201. doi: 10.4161/pri.3.4.9981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Sisková Z, Sanyal NK, Orban A, et al. Reactive hypertrophy of synaptic varicosities within the hippocampus of prion-infected mice. Biochem Soc Trans. 2010;38:471–475. doi: 10.1042/BST0380471. [DOI] [PubMed] [Google Scholar]
  • 50.Masliah E. Mechanisms of synaptic pathology in Alzheimer’s disease. J Neural Transm Suppl. 1998;53:147–158. doi: 10.1007/978-3-7091-6467-9_13. [DOI] [PubMed] [Google Scholar]
  • 51.Palop JJ, Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks. Nat Neurosci. 2010;13:812–818. doi: 10.1038/nn.2583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276:2045–2047. doi: 10.1126/science.276.5321.2045. [DOI] [PubMed] [Google Scholar]
  • 53.Singleton AB, Farrer MJ, Johnson J, et al. alpha-Synuclein locus triplication causes Parkinson’s disease. Science. 2003;302:841. doi: 10.1126/science.1090278. [DOI] [PubMed] [Google Scholar]
  • 54.Simón-Sánchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet. 2009;41:1308–1312. doi: 10.1038/ng.487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Fortin DL, Nemani VM, Voglmaier SM, et al. Neural activity controls the synaptic accumulation of alpha-synuclein. J Neurosci. 2005;25:10913–10921. doi: 10.1523/JNEUROSCI.2922-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Burré J, Sharma M, Tsetsenis T, et al. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010;329:1663–1667. doi: 10.1126/science.1195227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Chandra S, Gallardo G, Fernández-Chacón R, et al. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell. 2005;123:383–396. doi: 10.1016/j.cell.2005.09.028. [DOI] [PubMed] [Google Scholar]
  • 58.Quilty MC, King AE, Gai W-P, et al. Alpha-synuclein is upregulated in neurones in response to chronic oxidative stress and is associated with neuroprotection. Exp Neurol. 2006;199:249–256. doi: 10.1016/j.expneurol.2005.10.018. [DOI] [PubMed] [Google Scholar]
  • 59.Nemani VM, Lu W, Berge V, et al. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron. 2010;65:66–79. doi: 10.1016/j.neuron.2009.12.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Schulz-Schaeffer WJ. The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia. Acta Neuropathologica. 2010;120:131–143. doi: 10.1007/s00401-010-0711-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Piccoli G, Condliffe SB, Bauer M, et al. LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J Neurosci. 2011;31:2225–2237. doi: 10.1523/JNEUROSCI.3730-10.2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Shin N, Jeong H, Kwon J, et al. LRRK2 regulates synaptic vesicle endocytosis. Exp Cell Res. 2008;314:2055–2065. doi: 10.1016/j.yexcr.2008.02.015. [DOI] [PubMed] [Google Scholar]
  • 63.Conway KA, Rochet JC, Bieganski RM, Lansbury PT. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science. 2001;294:1346–1349. doi: 10.1126/science.1063522. [DOI] [PubMed] [Google Scholar]
  • 64.Leong SL, Cappai R, Barnham KJ, Pham CLL. Modulation of alpha-synuclein aggregation by dopamine: a review. Neurochem Res. 2009;34:1838–1846. doi: 10.1007/s11064-009-9986-8. [DOI] [PubMed] [Google Scholar]
  • 65.Perier C, Vila M. Mitochondrial biology and Parkinson’s disease. Cold Spring Harb Perspect Med. 2012;2:a009332. doi: 10.1101/cshperspect.a009332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Tai H-C, Schuman EM. Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction. Nat Rev Neurosci. 2008;9:826–838. doi: 10.1038/nrn2499. [DOI] [PubMed] [Google Scholar]
  • 67.Youle RJ, Van der Bliek AM. Mitochondrial fission, fusion, and stress. Science. 2012;337:1062–1065. doi: 10.1126/science.1219855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Schapira AHV, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem. 1990;54:823–827. doi: 10.1111/j.1471-4159.1990.tb02325.x. [DOI] [PubMed] [Google Scholar]
  • 69.Parker WD, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Ann Neurol. 1989;26:719–723. doi: 10.1002/ana.410260606. [DOI] [PubMed] [Google Scholar]
  • 70.Koopman W, Willems P (2012) Monogenic mitochondrial disorders. New Engl J Med [DOI] [PubMed]
  • 71.Matsuda N, Sato S, Shiba K, et al. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol. 2010;189:211–221. doi: 10.1083/jcb.200910140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Plun-Favreau H, Klupsch K, Moisoi N, et al. The mitochondrial protease HtrA2 is regulated by Parkinson’s disease-associated kinase PINK1. Nature Cell Biol. 2007;9:1243–1252. doi: 10.1038/ncb1644. [DOI] [PubMed] [Google Scholar]
  • 73.Pridgeon JW, Olzmann J a, Chin L-S, Li L. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol. 2007;5:e172. doi: 10.1371/journal.pbio.0050172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Chan NC, Salazar AM, Pham AH, et al. Broad activation of the ubiquitin–proteasome system by Parkin is critical for mitophagy. Hum Mol Genet. 2011;20:1726–1737. doi: 10.1093/hmg/ddr048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Gegg ME, Cooper JM, Chau K-Y, et al. Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. Hum Mol Genet. 2010;19:4861–4870. doi: 10.1093/hmg/ddq419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Geisler S, Holmström KM, Skujat D, et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nature Cell Biol. 2010;12:119–131. doi: 10.1038/ncb2012. [DOI] [PubMed] [Google Scholar]
  • 77.Shin J-H, Ko HS, Kang H, et al. PARIS (ZNF746) Repression of PGC-1α contributes to neurodegeneration in Parkinson’s disease. Cell. 2011;144:689–702. doi: 10.1016/j.cell.2011.02.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Scarpulla RC. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol Rev. 2008;88:611–638. doi: 10.1152/physrev.00025.2007. [DOI] [PubMed] [Google Scholar]
  • 79.Ryan MT, Hoogenraad NJ. Mitochondrial-nuclear communications. Annu Rev Biochem. 2007;76:701–722. doi: 10.1146/annurev.biochem.76.052305.091720. [DOI] [PubMed] [Google Scholar]
  • 80.Gandhi S, Wood-Kaczmar A, Yao Z, et al. PINK1-associated Parkinson’s disease is caused by neuronal vulnerability to calcium-induced cell death. Molecular Cell. 2009;33:627–638. doi: 10.1016/j.molcel.2009.02.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Yao Z, Gandhi S, Burchell VS, et al. Cell metabolism affects selective vulnerability in PINK1-associated Parkinson’s disease. J Cell Sci. 2011;124:4194–4202. doi: 10.1242/jcs.088260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Tschopp J. Mitochondria: Sovereign of inflammation? Eur J Immunol. 2011;41:1196–1202. doi: 10.1002/eji.201141436. [DOI] [PubMed] [Google Scholar]
  • 83.Thomas KJ, McCoy MK, Blackinton J, et al. DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Hum Mol Genet. 2011;20:40–50. doi: 10.1093/hmg/ddq430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Burbulla LF, Schelling C, Kato H, et al. Dissecting the role of the mitochondrial chaperone mortalin in Parkinson’s disease: functional impact of disease-related variants on mitochondrial homeostasis. Hum Mol Genet. 2010;19:4437–4452. doi: 10.1093/hmg/ddq370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Yang H, Zhou X, Liu X, et al. Mitochondrial dysfunction induced by knockdown of mortalin is rescued by Parkin. Biochem Biophys Res Commun. 2011;410:114–120. doi: 10.1016/j.bbrc.2011.05.116. [DOI] [PubMed] [Google Scholar]
  • 86.Weihofen A, Thomas KJ, Ostaszewski BL, et al. Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. Biochemistry. 2009;48:2045–2052. doi: 10.1021/bi8019178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Wang X, Winter D, Ashrafi G, et al. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell. 2011;147:893–906. doi: 10.1016/j.cell.2011.10.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Pilsl A, Winklhofer KF. Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson’s disease. Acta Neuropathol. 2012;123:173–188. doi: 10.1007/s00401-011-0902-3. [DOI] [PubMed] [Google Scholar]
  • 89.Sheng Z-H, Cai Q. Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration. Nat Rev Neurosci. 2012;13:77–93. doi: 10.1038/nrn3156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Lee H-J, Khoshaghideh F, Lee S, Lee S-J. Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein. Eur J Neurosci. 2006;24:3153–3162. doi: 10.1111/j.1460-9568.2006.05210.x. [DOI] [PubMed] [Google Scholar]
  • 91.Yang F, Jiang Q, Zhao J, et al. Parkin stabilizes microtubules through strong binding mediated by three independent domains. J Biol Chem. 2005;280:17154–17162. doi: 10.1074/jbc.M500843200. [DOI] [PubMed] [Google Scholar]
  • 92.Gillardon F. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability—a point of convergence in parkinsonian neurodegeneration? J Neurochem. 2009;110:1514–1522. doi: 10.1111/j.1471-4159.2009.06235.x. [DOI] [PubMed] [Google Scholar]
  • 93.Borland MK, Trimmer PA, Rubinstein JD, et al. Chronic, low-dose rotenone reproduces Lewy neurites found in early stages of Parkinson’s disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells. Mol Neurodegener. 2008;3:21. doi: 10.1186/1750-1326-3-21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Park D-W, Nam M-K, Rhim H. The serine protease HtrA2 cleaves UCH-L1 and inhibits its hydrolase activity: implication in the UCH-L1-mediated cell death. Biochem Biophys Res Commun. 2011;415:24–29. doi: 10.1016/j.bbrc.2011.09.148. [DOI] [PubMed] [Google Scholar]
  • 95.Gusdon AM, Zhu J, Van Houten B, Chu CT. ATP13A2 regulates mitochondrial bioenergetics through macroautophagy. Neurobiol Dis. 2012;45:962–972. doi: 10.1016/j.nbd.2011.12.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Braschi E, Goyon V, Zunino R, et al. Vps35 mediates vesicle transport between the mitochondria and peroxisomes. Curr Biol. 2010;20:1310–1315. doi: 10.1016/j.cub.2010.05.066. [DOI] [PubMed] [Google Scholar]
  • 97.Chartier-Harlin M-C, Dachsel JC, Vilariño-Güell C, et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet. 2011;89:398–406. doi: 10.1016/j.ajhg.2011.08.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Lee J, Giordano S, Zhang J. Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochem J. 2012;441:523–540. doi: 10.1042/BJ20111451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Korolchuk VI, Menzies FM, Rubinsztein DC. Mechanisms of cross-talk between the ubiquitin–proteasome and autophagy–lysosome systems. FEBS Lett. 2010;584:1393–1398. doi: 10.1016/j.febslet.2009.12.047. [DOI] [PubMed] [Google Scholar]
  • 100.Kroemer G, Mariño G, Levine B. Autophagy and the integrated stress response. Molecular cell. 2010;40:280–293. doi: 10.1016/j.molcel.2010.09.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Ravikumar B, Sarkar S, Davies JE, et al. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev. 2010;90:1383–1435. doi: 10.1152/physrev.00030.2009. [DOI] [PubMed] [Google Scholar]
  • 102.Harris H, Rubinsztein DC. Control of autophagy as a therapy for neurodegenerative disease. Nat Rev Neurol. 2011;8:108–117. doi: 10.1038/nrneurol.2011.200. [DOI] [PubMed] [Google Scholar]
  • 103.Martinez-Vicente M, Talloczy Z, Kaushik S, et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Investig. 2008;118:777–788. doi: 10.1172/JCI32806. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Nalls MA, Plagnol V, Hernandez DG, et al. Imputation of sequence variants for identification of genetic risks for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet. 2011;377:641–649. doi: 10.1016/S0140-6736(10)62345-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105.Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher’s disease. Lancet. 2008;372:1263–1271. doi: 10.1016/S0140-6736(08)61522-6. [DOI] [PubMed] [Google Scholar]
  • 106.Yap TL, Gruschus JM, Velayati A, et al. {alpha}-Synuclein interacts with glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J Biol Chem. 2011;286:28080–28088. doi: 10.1074/jbc.M111.237859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Westbroek W, Gustafson AM, Sidransky E. Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol Med. 2011;17:485–493. doi: 10.1016/j.molmed.2011.05.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, et al. Chaperone-mediated autophagy markers in Parkinson disease brains. Arch Neurol. 2010;67:1464–1472. doi: 10.1001/archneurol.2010.198. [DOI] [PubMed] [Google Scholar]
  • 109.Crews L, Spencer B, Desplats P, et al. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One. 2010;5:e9313. doi: 10.1371/journal.pone.0009313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110.Chu Y, Dodiya H, Aebischer P, et al. Alterations in lysosomal and proteasomal markers in Parkinson’s disease: relationship to alpha-synuclein inclusions. Neurobiol Dis. 2009;35:385–398. doi: 10.1016/j.nbd.2009.05.023. [DOI] [PubMed] [Google Scholar]
  • 111.Xu M, Zhang H. Death and survival of neuronal and astrocytic cells in ischemic brain injury: a role of autophagy. Acta Pharmacol Sin. 2011;32:1089–1099. doi: 10.1038/aps.2011.50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112.Chu CT. Autophagic stress in neuronal injury and disease. J Neuropathol Exp Neurol. 2006;65:423–432. doi: 10.1097/01.jnen.0000229233.75253.be. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Schapira AHV. Targeting mitochondria for neuroprotection in Parkinson’s disease. Antioxid Redox Signal. 2012;16:965–973. doi: 10.1089/ars.2011.4419. [DOI] [PubMed] [Google Scholar]
  • 114.Nixon RA, Yang D-S. Autophagy failure in Alzheimer’s disease—locating the primary defect. Neurobiol Dis. 2011;43:38–45. doi: 10.1016/j.nbd.2011.01.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115.Pickford F, Masliah E, Britschgi M, et al. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Investig. 2008;118:2190–2199. doi: 10.1172/JCI33585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116.Yang D-S, Stavrides P, Mohan PS, et al. Therapeutic effects of remediating autophagy failure in a mouse model of Alzheimer disease by enhancing lysosomal proteolysis. Autophagy. 2011;7:788–789. doi: 10.4161/auto.7.7.15596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 117.Komatsu M, Waguri S, Chiba T, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006;441:880–884. doi: 10.1038/nature04723. [DOI] [PubMed] [Google Scholar]
  • 118.Hara T, Nakamura K, Matsui M, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature. 2006;441:885–889. doi: 10.1038/nature04724. [DOI] [PubMed] [Google Scholar]
  • 119.Breydo L, Wu JW, Uversky VN. α-Synuclein misfolding and Parkinson’s disease. Biochim Biophys Acta. 2012;1822:261–285. doi: 10.1016/j.bbadis.2011.10.002. [DOI] [PubMed] [Google Scholar]
  • 120.Ullman O, Fisher CK, Stultz CM. Explaining the structural plasticity of α-synuclein. J Am Chem Soc. 2011;133:19536–19546. doi: 10.1021/ja208657z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121.Wang W, Perovic I, Chittuluru J, et al. A soluble α-synuclein construct forms a dynamic tetramer. PNAS. 2011;108:17797–17802. doi: 10.1073/pnas.1113260108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122.Bartels T, Choi JG, Selkoe DJ (2011) α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 3–7. doi: 10.1038/nature10324 [DOI] [PMC free article] [PubMed]
  • 123.Lee S-J, Lim H-S, Masliah E, Lee H-J. Protein aggregate spreading in neurodegenerative diseases: Problems and perspectives. Neurosci Res. 2011;70:339–348. doi: 10.1016/j.neures.2011.05.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 124.Yonetani M, Nonaka T, Masuda M, et al. Conversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant. J Biol Chem. 2009;284:7940–7950. doi: 10.1074/jbc.M807482200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 125.Colla E, Jensen PH, Pletnikova O, et al. Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. J Neurosci. 2012;32:3301–3305. doi: 10.1523/JNEUROSCI.5368-11.2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126.Chung CY, Koprich JB, Siddiqi H, Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci. 2009;29:3365–3373. doi: 10.1523/JNEUROSCI.5427-08.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127.Ihara M, Yamasaki N, Hagiwara A, et al. Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity. Neuron. 2007;53:519–533. doi: 10.1016/j.neuron.2007.01.019. [DOI] [PubMed] [Google Scholar]
  • 128.Kahle PJ, Neumann M, Ozmen L, et al. Subcellular localization of wild-type and Parkinson’s disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J Neurosci. 2000;20:6365–6373. doi: 10.1523/JNEUROSCI.20-17-06365.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 129.Yavich L, Jäkälä P, Tanila H. Abnormal compartmentalization of norepinephrine in mouse dentate gyrus in alpha-synuclein knockout and A30P transgenic mice. J Neurochem. 2006;99:724–732. doi: 10.1111/j.1471-4159.2006.04098.x. [DOI] [PubMed] [Google Scholar]
  • 130.Martin LJ, Pan Y, Price AC, et al. Parkinson’s disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci. 2006;26:41–50. doi: 10.1523/JNEUROSCI.4308-05.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 131.Devi L, Raghavendran V, Prabhu BM, et al. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem. 2008;283:9089–9100. doi: 10.1074/jbc.M710012200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 132.Loeb V, Yakunin E, Saada A, Sharon R. The transgenic overexpression of alpha-synuclein and not its related pathology associates with complex I inhibition. J Biol Chem. 2010;285:7334–7343. doi: 10.1074/jbc.M109.061051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 133.Chinta SJ, Mallajosyula JK, Rane A, Andersen JK. Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett. 2010;486:235–239. doi: 10.1016/j.neulet.2010.09.061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 134.Choubey V, Safiulina D, Vaarmann A, et al. Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem. 2011;286:10814–10824. doi: 10.1074/jbc.M110.132514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 135.Esposito A, Dohm CP, Kermer P, et al. alpha-Synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton. Neurobiol Dis. 2007;26:521–531. doi: 10.1016/j.nbd.2007.01.014. [DOI] [PubMed] [Google Scholar]
  • 136.Lee H-J, Shin SY, Choi C, et al. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J Biol Chem. 2002;277:5411–5417. doi: 10.1074/jbc.M105326200. [DOI] [PubMed] [Google Scholar]
  • 137.Chen L, Jin J, Davis J, et al. Oligomeric α-synuclein inhibits tubulin polymerization. Biochem Biophys Res Commun. 2007;356:548–553. doi: 10.1016/j.bbrc.2007.02.163. [DOI] [PubMed] [Google Scholar]
  • 138.Jensen PH. alpha -Synuclein binds to tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J Biol Chem. 1999;274:25481–25489. doi: 10.1074/jbc.274.36.25481. [DOI] [PubMed] [Google Scholar]
  • 139.Frasier M, Walzer M, McCarthy L, et al. Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein. Exp Neurol. 2005;192:274–287. doi: 10.1016/j.expneurol.2004.07.016. [DOI] [PubMed] [Google Scholar]
  • 140.Haggerty T, Credle J, Rodriguez O, et al. Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson’s disease. Eur J Neurosci. 2011;33:1598–1610. doi: 10.1111/j.1460-9568.2011.07660.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 141.Qureshi HY, Paudel HK. Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and alpha-synuclein mutations promote Tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitro. J Biol Chem. 2011;286:5055–5068. doi: 10.1074/jbc.M110.178905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 142.Clinton LK, Blurton-Jones M, Myczek K, et al. Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci. 2010;30:7281–7289. doi: 10.1523/JNEUROSCI.0490-10.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 143.Giasson BI, Forman MS, Higuchi M, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science. 2003;300:636–640. doi: 10.1126/science.1082324. [DOI] [PubMed] [Google Scholar]
  • 144.Smith WW, Jiang H, Pei Z, et al. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum Mol Genet. 2005;14:3801–3811. doi: 10.1093/hmg/ddi396. [DOI] [PubMed] [Google Scholar]
  • 145.Colla E, Coune P, Liu Y, et al. Endoplasmic reticulum stress is important for the manifestations of α-synucleinopathy in vivo. J Neurosci. 2012;32:3306–3320. doi: 10.1523/JNEUROSCI.5367-11.2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 146.Cuervo AM, Stefanis L, Fredenburg R, et al. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004;305:1292–1295. doi: 10.1126/science.1101738. [DOI] [PubMed] [Google Scholar]
  • 147.Xilouri M, Vogiatzi T, Vekrellis K, et al. Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS One. 2009;4:e5515. doi: 10.1371/journal.pone.0005515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 148.Mazzulli JR, Xu Y-H, Sun Y, et al. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146:37–52. doi: 10.1016/j.cell.2011.06.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 149.Tanaka Y, Engelender S, Igarashi S, et al. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet. 2001;10:919–926. doi: 10.1093/hmg/10.9.919. [DOI] [PubMed] [Google Scholar]
  • 150.Stefanis L, Larsen KE, Rideout HJ, et al. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci. 2001;21:9549–9560. doi: 10.1523/JNEUROSCI.21-24-09549.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 151.Petrucelli L, O’Farrell C, Lockhart PJ, et al. Parkin protects against the toxicity associated with mutant α-synuclein proteasome dysfunction selectively affects catecholaminergic neurons. Neuron. 2002;36:1007–1019. doi: 10.1016/s0896-6273(02)01125-x. [DOI] [PubMed] [Google Scholar]
  • 152.Lindersson E, Beedholm R, Højrup P, et al. Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem. 2004;279:12924–12934. doi: 10.1074/jbc.M306390200. [DOI] [PubMed] [Google Scholar]
  • 153.Goedert M, Clavaguera F, Tolnay M. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci. 2010;33:317–325. doi: 10.1016/j.tins.2010.04.003. [DOI] [PubMed] [Google Scholar]
  • 154.Kordower JH, Chu Y, Hauser RA, et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nature Medicine. 2008;14:504–506. doi: 10.1038/nm1747. [DOI] [PubMed] [Google Scholar]
  • 155.Kordower JH, Chu Y, Hauser RA, et al. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord. 2008;23:2303–2306. doi: 10.1002/mds.22369. [DOI] [PubMed] [Google Scholar]
  • 156.Li J-Y, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nature Medicine. 2008;14:501–503. doi: 10.1038/nm1746. [DOI] [PubMed] [Google Scholar]
  • 157.Desplats P, Lee H-J, Bae E-J, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. PNAS. 2009;106:13010–13015. doi: 10.1073/pnas.0903691106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 158.Volpicelli-Daley LA, Luk KC, Patel TP, et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2011;72:57–71. doi: 10.1016/j.neuron.2011.08.033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 159.Luk KC, Kehm V, Carroll J, et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338:949–953. doi: 10.1126/science.1227157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 160.Jang A, Lee H-J, Suk J-E, et al. Non-classical exocytosis of alpha-synuclein is sensitive to folding states and promoted under stress conditions. J Neurochem. 2010;113:1263–1274. doi: 10.1111/j.1471-4159.2010.06695.x. [DOI] [PubMed] [Google Scholar]
  • 161.Lee H-J, Patel S, Lee S-J. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci. 2005;25:6016–6024. doi: 10.1523/JNEUROSCI.0692-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 162.Luk KC, Song C, O’Brien P, et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. PNAS. 2009;106:20051–20056. doi: 10.1073/pnas.0908005106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 163.Mosley RL, Hutter-Saunders JA, Stone DK, Gendelman HE (2012) Inflammation and adaptive immunity in Parkinson’s disease. Cold Spring Harbor perspectives in medicine 2:a009381. [DOI] [PMC free article] [PubMed]
  • 164.McGeer PL, Itagaki S, Akiyama H, McGeer EG. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol. 1988;24:574–576. doi: 10.1002/ana.410240415. [DOI] [PubMed] [Google Scholar]
  • 165.Brochard V, Combadière B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Investig. 2009;119:182–192. doi: 10.1172/JCI36470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 166.Double KL, Rowe DB, Carew-Jones FM, et al. Anti-melanin antibodies are increased in sera in Parkinson’s disease. Exp Neurol. 2009;217:297–301. doi: 10.1016/j.expneurol.2009.03.002. [DOI] [PubMed] [Google Scholar]
  • 167.Reynolds AD, Stone DK, Hutter J a L, et al. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J Immunol. 2010;184:2261–2271. doi: 10.4049/jimmunol.0901852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 168.Lucin KM, Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron. 2009;64:110–122. doi: 10.1016/j.neuron.2009.08.039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 169.Glass CK, Saijo K, Winner B, et al. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140:918–934. doi: 10.1016/j.cell.2010.02.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 170.Rocha SM, Cristovão AC, Campos FL, et al. Astrocyte-derived GDNF is a potent inhibitor of microglial activation. Neurobiol Dis. 2012;47:407–415. doi: 10.1016/j.nbd.2012.04.014. [DOI] [PubMed] [Google Scholar]
  • 171.Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308:1314–1318. doi: 10.1126/science.1110647. [DOI] [PubMed] [Google Scholar]
  • 172.Davalos D, Grutzendler J, Yang G, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci. 2005;8:752–758. doi: 10.1038/nn1472. [DOI] [PubMed] [Google Scholar]
  • 173.Mott RT, Ait-Ghezala G, Town T, et al. Neuronal expression of CD22: novel mechanism for inhibiting microglial proinflammatory cytokine production. Glia. 2004;46:369–379. doi: 10.1002/glia.20009. [DOI] [PubMed] [Google Scholar]
  • 174.Majed HH, Chandran S, Niclou SP, et al. A novel role for Sema3A in neuroprotection from injury mediated by activated microglia. J Neurosci. 2006;26:1730–1738. doi: 10.1523/JNEUROSCI.0702-05.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 175.Tian L, Rauvala H, Gahmberg CG. Neuronal regulation of immune responses in the central nervous system. Trends Immunol. 2009;30:91–99. doi: 10.1016/j.it.2008.11.002. [DOI] [PubMed] [Google Scholar]
  • 176.Koning N, Bö L, Hoek RM, Huitinga I. Downregulation of macrophage inhibitory molecules in multiple sclerosis lesions. Ann Neurol. 2007;62:504–514. doi: 10.1002/ana.21220. [DOI] [PubMed] [Google Scholar]
  • 177.Cardona AE, Pioro EP, Sasse ME, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci. 2006;9:917–924. doi: 10.1038/nn1715. [DOI] [PubMed] [Google Scholar]
  • 178.Kim WG, Mohney RP, Wilson B, et al. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci: Off J Soc Neurosci. 2000;20:6309–6316. doi: 10.1523/JNEUROSCI.20-16-06309.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 179.Mena M a, Yébenes G d J. Immune activation in brain aging and neurodegeneration: too much or too little? Neuroscientist. 2008;14:544–560. [Google Scholar]
  • 180.Zecca L, Wilms H, Geick S, et al. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson’s disease. Acta Neuropathol. 2008;116:47–55. doi: 10.1007/s00401-008-0361-7. [DOI] [PubMed] [Google Scholar]
  • 181.McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer's disease brains. Neurology. 1988;38:1285–1285. doi: 10.1212/wnl.38.8.1285. [DOI] [PubMed] [Google Scholar]
  • 182.Langston JW, Forno LS, Tetrud J, et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol. 1999;46:598–605. doi: 10.1002/1531-8249(199910)46:4<598::aid-ana7>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  • 183.McGeer PL, Schwab C, Parent A, Doudet D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol. 2003;54:599–604. doi: 10.1002/ana.10728. [DOI] [PubMed] [Google Scholar]
  • 184.Czlonkowska A, Kohutnicka M, Kurkowska-Jastrzebska I, Czlonkowski A. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson’s disease mice model. Neurodegeneration. 1996;5:137–143. doi: 10.1006/neur.1996.0020. [DOI] [PubMed] [Google Scholar]
  • 185.Walsh S, Finn DP, Dowd E. Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson’s disease in the rat. Neuroscience. 2011;175:251–261. doi: 10.1016/j.neuroscience.2010.12.005. [DOI] [PubMed] [Google Scholar]
  • 186.Gao H, Liu B, Zhang W, Hong J. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson’s disease. FASEB J. 2003;17:1954–1956. doi: 10.1096/fj.03-0109fje. [DOI] [PubMed] [Google Scholar]
  • 187.Zhang W, Wang T, Pei Z, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease. FASEB J. 2005;19:533–542. doi: 10.1096/fj.04-2751com. [DOI] [PubMed] [Google Scholar]
  • 188.Béraud D, Twomey M, Bloom B, et al. α-Synuclein alters Toll-like receptor expression. Frontiers in. Neuroscience. 2011;5:80. doi: 10.3389/fnins.2011.00080. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 189.Zhang W, Dallas S, Zhang D, et al. Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. Glia. 2007;55:1178–1188. doi: 10.1002/glia.20532. [DOI] [PubMed] [Google Scholar]
  • 190.Alvarez-Erviti L, Couch Y, Richardson J, et al. Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. Neurosci Res. 2011;69:337–342. doi: 10.1016/j.neures.2010.12.020. [DOI] [PubMed] [Google Scholar]
  • 191.Gillardon F, Schmid R, Draheim H. Parkinson’s disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience. 2012;208:41–48. doi: 10.1016/j.neuroscience.2012.02.001. [DOI] [PubMed] [Google Scholar]
  • 192.Frank-Cannon TC, Tran T, Ruhn K a, et al. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci. 2008;28:10825–10834. doi: 10.1523/JNEUROSCI.3001-08.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 193.Waak J, Weber SS, Waldenmaier A, et al. Regulation of astrocyte inflammatory responses by the Parkinson’s disease-associated gene DJ-1. FASEB J. 2009;23:2478–2489. doi: 10.1096/fj.08-125153. [DOI] [PubMed] [Google Scholar]
  • 194.Wu DC, Jackson-Lewis V, Vila M, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci. 2002;22:1763–1771. doi: 10.1523/JNEUROSCI.22-05-01763.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 195.Perier C, Bové J, Vila M. Mitochondria and programmed cell death in Parkinson’s disease: apoptosis and beyond. Antioxid Redox Signal. 2012;16:883–895. doi: 10.1089/ars.2011.4074. [DOI] [PubMed] [Google Scholar]
  • 196.Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9:47–59. doi: 10.1038/nrm2308. [DOI] [PubMed] [Google Scholar]
  • 197.Tait SWG, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11:621–632. doi: 10.1038/nrm2952. [DOI] [PubMed] [Google Scholar]
  • 198.Offen D, Beart PM, Cheung NS, et al. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. PNAS. 1998;95:5789–5794. doi: 10.1073/pnas.95.10.5789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 199.Yang L, Matthews RT, Schulz JB, et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J Neurosci. 1998;18:8145–8152. doi: 10.1523/JNEUROSCI.18-20-08145.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 200.Vila M, Jackson-Lewis V, Vukosavic S, et al. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. PNAS. 2001;98:2837–2842. doi: 10.1073/pnas.051633998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 201.Perier C, Bové J, Wu D-C, et al. Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson’s disease. PNAS. 2007;104:8161–8166. doi: 10.1073/pnas.0609874104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 202.Dietz GPH, Stockhausen KV, Dietz B, et al. Membrane-permeable Bcl-xL prevents MPTP-induced dopaminergic neuronal loss in the substantia nigra. J Neurochem. 2008;104:757–765. doi: 10.1111/j.1471-4159.2007.05028.x. [DOI] [PubMed] [Google Scholar]
  • 203.Iaccarino C, Crosio C, Vitale C, et al. Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet. 2007;16:1319–1326. doi: 10.1093/hmg/ddm080. [DOI] [PubMed] [Google Scholar]
  • 204.Darios F, Corti O, Lücking CB, et al. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet. 2003;12:517–526. doi: 10.1093/hmg/ddg044. [DOI] [PubMed] [Google Scholar]
  • 205.Petit A, Kawarai T, Paitel E, et al. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J Biol Chem. 2005;280:34025–34032. doi: 10.1074/jbc.M505143200. [DOI] [PubMed] [Google Scholar]
  • 206.Wang H-L, Chou A-H, Yeh T-H, et al. PINK1 mutants associated with recessive Parkinson’s disease are defective in inhibiting mitochondrial release of cytochrome c. Neurobiol Dis. 2007;28:216–226. doi: 10.1016/j.nbd.2007.07.010. [DOI] [PubMed] [Google Scholar]
  • 207.Boya P, Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene. 2008;27:6434–6451. doi: 10.1038/onc.2008.310. [DOI] [PubMed] [Google Scholar]
  • 208.Turk B, Turk DSA, Turk V. Protease signalling: the cutting edge. EMBO J. 2012;31:1630–1643. doi: 10.1038/emboj.2012.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 209.Jeon S-M, Cheon S-M, Bae H-R, et al. Selective susceptibility of human dopaminergic neural stem cells to dopamine-induced apoptosis. Exp Neurobiol. 2010;19:155–164. doi: 10.5607/en.2010.19.3.155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 210.Benner EJ, Banerjee R, Reynolds AD, et al. Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One. 2008;3:e1376. doi: 10.1371/journal.pone.0001376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 211.Gao H-M, Zhou H, Zhang F, et al. HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci. 2011;31:1081–1092. doi: 10.1523/JNEUROSCI.3732-10.2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 212.Simi A, Tsakiri N, Wang P, Rothwell NJ. Interleukin-1 and inflammatory neurodegeneration. Biochem Soc Trans. 2007;35:1122–1126. doi: 10.1042/BST0351122. [DOI] [PubMed] [Google Scholar]
  • 213.McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation. 2008;5:45. doi: 10.1186/1742-2094-5-45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 214.Magrane M, Consortium U (2011) UniProt Knowledgebase: a hub of integrated protein data. Database (Oxford) 2011:bar009. [DOI] [PMC free article] [PubMed]
  • 215.Seal RL, Gordon SM, Lush MJ, et al. genenames.org: the HGNC resources in 2011. Nucleic Acids Res. 2011;39:D514–D519. doi: 10.1093/nar/gkq892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 216.Cochrane G, Akhtar R, Bonfield J, et al. Petabyte-scale innovations at the European Nucleotide Archive. Nucleic Acids Res. 2009;37:19–25. doi: 10.1093/nar/gkn765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 217.Flicek P, Amode MR, Barrell D, et al. Ensembl 2012. Nucleic Acids Res. 2012;40:84–90. doi: 10.1093/nar/gkr991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 218.Fujita PA, Rhead B, Zweig AS, et al. The UCSC Genome Browser database: update 2011. Nucleic Acids Res. 2011;39:D876–D882. doi: 10.1093/nar/gkq963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 219.Pruitt KD, Tatusova T, Brown GR, Maglott DR. NCBI Reference Sequences (RefSeq): current status, new features and genome annotation policy. Nucleic Acids Res. 2012;40:D130–D135. doi: 10.1093/nar/gkr1079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 220.Maglott D, Ostell J, Pruitt KD, Tatusova T. Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res. 2011;39:D52–D57. doi: 10.1093/nar/gkq1237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 221.Schuler GD. Pieces of the puzzle: expressed sequence tags and the catalog of human genes. J Mol Med. 1997;75:694–698. doi: 10.1007/s001090050155. [DOI] [PubMed] [Google Scholar]
  • 222.Safran M, Dalah I, Alexander J, et al. (2010) Gene Cards Version 3: the human gene integrator. Database (Oxford) 2010:baq020. [DOI] [PMC free article] [PubMed]
  • 223.Berman H, Henrick K, Nakamura H, Markley JL. The worldwide Protein Data Bank (wwPDB): ensuring a single, uniform archive of PDB data. Nucleic Acids Res. 2007;35:D301–D303. doi: 10.1093/nar/gkl971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 224.Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25:25–29. doi: 10.1038/75556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 225.Kanehisa M, Goto S, Sato Y, et al. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 2012;40:D109–D114. doi: 10.1093/nar/gkr988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 226.Mi H, Lazareva-Ulitsky B, Loo R, et al. The PANTHER database of protein families, subfamilies, functions and pathways. Nucleic Acids Res. 2005;33:D284–D288. doi: 10.1093/nar/gki078. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 227.Croft D, O’Kelly G, Wu G, et al. Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res. 2011;39:D691–D697. doi: 10.1093/nar/gkq1018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 228.Punta M, Coggill PC, Eberhardt RY, et al. The Pfam protein families database. Nucleic Acids Res. 2012;40:290–301. doi: 10.1093/nar/gkr1065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 229.Hunter S, Jones P, Mitchell A, et al. InterPro in 2011: new developments in the family and domain prediction database. Nucleic Acids Res. 2012;40:D306–D312. doi: 10.1093/nar/gkr948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 230.cDonagh EM, Whirl-Carrillo M, Garten Y, et al. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark Med. 2011;5:795–806. doi: 10.2217/bmm.11.94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 231.Zhang Y, James M, Middleton FA, Davis RL. Transcriptional analysis of multiple brain regions in Parkinson’s disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. Am J Med Genet. 2005;137B:5–16. doi: 10.1002/ajmg.b.30195. [DOI] [PubMed] [Google Scholar]
  • 232.Lesnick TG, Papapetropoulos S, Mash DC, et al. A genomic pathway approach to a complex disease: axon guidance and Parkinson disease. PLoS Genet. 2007;3:12. doi: 10.1371/journal.pgen.0030098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 233.Moran LB, Duke DC, Deprez M, et al. Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson’s disease. Neurogenetics. 2006;7:1–11. doi: 10.1007/s10048-005-0020-2. [DOI] [PubMed] [Google Scholar]
  • 234.Zheng B, Liao Z, Locascio JJ, et al. PGC-1α, a potential therapeutic target for early intervention in Parkinson’s disease. Sci Transl Med. 2010;2:52ra–73ra. doi: 10.1126/scitranslmed.3001059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 235.Scherzer CR, Eklund AC, Morse LJ, et al. Molecular markers of early Parkinson’s disease based on gene expression in blood. PNAS. 2007;104:955–960. doi: 10.1073/pnas.0610204104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 236.Sforza D, Hartenstein P, Lacan G, et al. (2008) Gene expression changes in multiple brain regions of a mouse MPTP model of Parkinson’s disease. Fairfax, VA 22030 USA
  • 237.Foti R, Zucchelli S, Biagioli M, et al. Parkinson disease-associated DJ-1 is required for the expression of the glial cell line-derived neurotrophic factor receptor RET in human neuroblastoma cells. J Biol Chem. 2010;285:18565–18574. doi: 10.1074/jbc.M109.088294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 238.Rajagopalan D, Agarwal P. Inferring pathways from gene lists using a literature-derived network of biological relationships. Bioinformatics. 2005;21:788–793. doi: 10.1093/bioinformatics/bti069. [DOI] [PubMed] [Google Scholar]
  • 239.Ulitsky I, Shamir R. Identifying functional modules using expression profiles and confidence-scored protein interactions. Bioinformatics. 2009;25:1158–1164. doi: 10.1093/bioinformatics/btp118. [DOI] [PubMed] [Google Scholar]
  • 240.Cerami E, Demir E, Schultz N, et al. Automated network analysis identifies core pathways in glioblastoma. PLoS One. 2010;5:e8918. doi: 10.1371/journal.pone.0008918. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 241.Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. PNAS. 2001;98:5116–5121. doi: 10.1073/pnas.091062498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 242.Aerts S, Lambrechts D, Maity S, et al. Gene prioritization through genomic data fusion. Nat Biotechnol. 2006;24:537–544. doi: 10.1038/nbt1203. [DOI] [PubMed] [Google Scholar]
  • 243.Ma X, Lee H, Wang L, Sun F. CGI: a new approach for prioritizing genes by combining gene expression and protein–protein interaction data. Bioinformatics. 2007;23:215–221. doi: 10.1093/bioinformatics/btl569. [DOI] [PubMed] [Google Scholar]
  • 244.Zaykin DV, Zhivotovsky LA, Czika W, et al. Combining p-values in large-scale genomics experiments. Pharm Stat. 2007;6:217–226. doi: 10.1002/pst.304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 245.Marot G, Foulley J-L, Mayer C-D, Jaffrézic F. Moderated effect size and P-value combinations for microarray meta-analyses. Bioinformatics. 2009;25:2692–2699. doi: 10.1093/bioinformatics/btp444. [DOI] [PubMed] [Google Scholar]
  • 246.Aittokallio T, Schwikowski B. Graph-based methods for analysing networks in cell biology. Brief Bioinform. 2006;7:243–255. doi: 10.1093/bib/bbl022. [DOI] [PubMed] [Google Scholar]
  • 247.Emmert-Streib F, Dehmer M. Networks for systems biology: conceptual connection of data and function. IET Syst Biol. 2011;5:185. doi: 10.1049/iet-syb.2010.0025. [DOI] [PubMed] [Google Scholar]
  • 248.Junker BH, Schreiber F (2008) Analysis of biological networks. Science 1–28. doi:10.1002/9780470253489
  • 249.Guimerà R, Sales-Pardo M, Amaral LAN. Classes of complex networks defined by role-to-role connectivity profiles. Nat Phys. 2007;3:63–69. doi: 10.1038/nphys489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 250.Wang R-S, Albert R. Elementary signaling modes predict the essentiality of signal transduction network components. BMC Syst Biol. 2011;5:44. doi: 10.1186/1752-0509-5-44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 251.Klipp E, Liebermeister W. Mathematical modeling of intracellular signaling pathways. BMC Neurosci. 2006;7(Suppl 1):S10. doi: 10.1186/1471-2202-7-S1-S10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 252.Hucka M, Finney a, Sauro HM. The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics. 2003;19:524–531. doi: 10.1093/bioinformatics/btg015. [DOI] [PubMed] [Google Scholar]
  • 253.Hoops S, Sahle S, Gauges R, et al. COPASI—a COmplex PAthway SImulator. Bioinform (Oxford, England) 2006;22:3067–3074. doi: 10.1093/bioinformatics/btl485. [DOI] [PubMed] [Google Scholar]
  • 254.Van Eunen K, Kiewiet J a L, Westerhoff HV, Bakker BM. Testing biochemistry revisited: how in vivo metabolism can be understood from in vitro enzyme kinetics. PLoS Comput Biol. 2012;8:e1002483. doi: 10.1371/journal.pcbi.1002483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 255.Kowald A, Hamann A, Zintel S, et al. A systems biological analysis links ROS metabolism to mitochondrial protein quality control. MechAgeing Dev. 2012;133:331–337. doi: 10.1016/j.mad.2012.03.008. [DOI] [PubMed] [Google Scholar]
  • 256.Berndt N, Bulik S, Holzhütter H-G (2012) Kinetic modeling of the mitochondrial energy metabolism of neuronal cells: the impact of reduced α-ketoglutarate dehydrogenase activities on ATP production and generation of reactive oxygen species. International journal of cell biology 2012:757594. doi: 10.1155/2012/757594 [DOI] [PMC free article] [PubMed]
  • 257.Craddock TJ a, Tuszynski J a, Chopra D, et al. The zinc dyshomeostasis hypothesis of Alzheimer’s disease. PLoS One. 2012;7:e33552. doi: 10.1371/journal.pone.0033552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 258.Ambert N, Greget R, Haeberlé O, et al. Computational studies of NMDA receptors: differential effects of neuronal activity on efficacy of competitive and non-competitive antagonists. Open Access Bioinforma. 2010;2:113–125. doi: 10.2147/OAB.S7246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 259.Berardini TZ, Li D, Muller R, et al. (2012) Assessment of community-submitted ontology annotations from a novel database-journal partnership. Database : the journal of biological databases and curation 2012:bas030. doi: 10.1093/database/bas030 [DOI] [PMC free article] [PubMed]
  • 260.Meyer P, Alexopoulos LG, Bonk T, et al. Verification of systems biology research in the age of collaborative competition. Nat Biotechnol. 2011;29:811–815. doi: 10.1038/nbt.1968. [DOI] [PubMed] [Google Scholar]
  • 261.Meyer P, Hoeng J, Rice JJ, et al. Industrial methodology for process verification in research (IMPROVER): toward systems biology verification. Bioinform (Oxford, England) 2012;28:1193–1201. doi: 10.1093/bioinformatics/bts116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 262.Nielsen MA. Reinventing discovery: the new era of networked science. Princeton, NJ: Princeton University Press; 2011. [Google Scholar]
  • 263.Kelder T, Van Iersel MP, Hanspers K, et al. WikiPathways: building research communities on biological pathways. Nucleic Acids Res. 2012;40:D1301–D1307. doi: 10.1093/nar/gkr1074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 264.Matsuoka Y, Ghosh S, Kikuchi N, Kitano H. Payao: a community platform for SBML pathway model curation. Bioinformatics. 2010;26:1381–1383. doi: 10.1093/bioinformatics/btq143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 265.Le Novère N, Hucka M, Mi H, et al. The systems biology graphical notation. Nat Biotechnol. 2009;27:735–741. doi: 10.1038/nbt.1558. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

ESM 1 (213.9KB, pdf)

(PDF 211 kb)

ESM 2 (11.4MB, xml)

(XML 11.3 mb)

ESM 3 (404.8KB, pdf)

(PDF 404 kb)

ESM 4 (137.2KB, pdf)

(PDF 137 kb)

ESM 5 (290.4KB, pdf)

(PDF 290 kb)


Articles from Molecular Neurobiology are provided here courtesy of Springer

RESOURCES